Phathom Pharmaceuticals Q2 2026 Earnings Report

Phathom Pharmaceuticals EPS Results

• Actual EPS: N/A
• Consensus EPS: -$0.21
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Phathom Pharmaceuticals Revenue Results

• Actual Revenue: N/A
• Expected Revenue: $73.98 million
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Phathom Pharmaceuticals Announcement Details

• Quarter: Q2 2026
• Date: 8/6/2026
• Time: Before Market Opens
• Conference Call Date: Thursday, August 6, 2026
• Conference Call Time: 8:00AM ET

Phathom Pharmaceuticals (NASDAQ:PHAT) is a clinical‐stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases. The company’s core mission centers on addressing serious GI disorders by leveraging innovative mechanisms of action to improve patient outcomes. Phathom’s research and development efforts concentrate on conditions such as Helicobacter pylori infection, erosive esophagitis, gastroparesis and other functional GI disorders where significant unmet medical needs persist.

The company’s lead asset is vonoprazan, a potassium‐competitive acid blocker (P-CAB) licensed for use in the United States. In May 2022, the U.S. Food and Drug Administration approved Phathom’s vonoprazan‐based triple therapy regimen, marketed under the brand name Voquezna™ Triple Pak, for first‐line treatment of H. pylori infection. Phathom has also pursued additional filings for vonoprazan in erosive esophagitis and other acid‐related disorders. Beyond vonoprazan, Phathom’s pipeline includes investigational compounds in earlier stages of clinical development targeting gastroparesis and functional dyspepsia.

Founded in 2018 and headquartered in Redwood City, California, Phathom Pharmaceuticals completed its initial public offering in October 2020 and trades on the NASDAQ under the ticker symbol PHAT. The company was established to build a specialty GI franchise by acquiring and advancing differentiated assets in gastroenterology. Phathom operates a lean organizational structure, collaborating with clinical investigators and strategic partners to conduct trials and prepare regulatory submissions.

Under the leadership of President and Chief Executive Officer Dan Lynch, Phathom continues to expand its commercial infrastructure to support product launches and market access efforts in the United States. The company is also exploring partnerships and licensing arrangements to extend its reach into international markets. With a focus on high‐impact GI indications and a growing portfolio of late-stage programs, Phathom aims to become a leader in therapies that address chronic and serious gastrointestinal diseases.